Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company operating as Dyadic Applied BioSolutions, has entered into definitive agreements with an institutional investor for a registered direct offering of 3,625,000 common shares and a concurrent private placement of warrants to purchase an equal number of shares. The common shares are priced at $0.795 each, with warrants priced at $0.005 each and an exercise price of $0.84 per share. The transactions are expected to generate aggregate gross proceeds of approximately $2.9 million, with closing anticipated on or about Aug. 14, 2026, subject to customary closing conditions.
The company intends to use the net proceeds, along with existing cash, cash equivalents, restricted cash, and investment-grade securities, for working capital and general corporate purposes. This capital infusion is aimed at supporting Dyadic's ongoing efforts to develop and commercialize its proprietary protein production platforms, which are designed to meet the growing global demand for sustainable, non-animal proteins across the life sciences, food and nutrition, and bio-industrial markets.
Dyadic's proprietary Dapibus™ and C1 expression systems are central to its value proposition, enabling rapid, cost-effective, and flexible manufacturing of high-value proteins. These platforms are intended to help customers develop more efficient, scalable, and sustainable products. The company's focus on non-animal protein production aligns with broader industry trends toward sustainability and ethical sourcing, making this funding round a strategic move to capitalize on market opportunities.
The offering is being led by Aegis Capital Corp. as the exclusive placement agent. This financial move reflects investor confidence in Dyadic's technology and market positioning. As the company advances its pipeline, the additional capital will support operational needs and potential growth initiatives.
For more details on the offering, visit the full press release at https://ibn.fm/od7FJ. Dyadic International's commitment to innovation in biotechnology positions it to play a significant role in the transition to more sustainable protein sources, which is increasingly important for global food security and environmental sustainability.
